Stent Plus Medicine Matches Medicine Alone Long-Term
Extended COURAGE trial follow-up finds no significant difference in death or heart attack risk for stable coronary artery disease.
Updated on Nov. 20, 2026 in Heart Disease

Live Poll
Would you want a stent if your doctor said your heart artery was narrowed?
A long-term follow-up of the COURAGE trial found no significant difference in death or heart attack risk between patients who received a stent plus medical therapy and those given medical therapy alone for stable coronary artery disease. The findings were published in JAMA and presented at the 2026 American Heart Association Scientific Sessions.
Why it matters
The results add long-run evidence to the question of whether widening narrowed arteries with stents offers benefit beyond optimized medication for people with stable disease. The analysis was observational and relied on routinely collected health records, so researchers noted limits in identifying heart attacks this way.
The study tracked 959 participants with a 15-year median follow-up, with some followed for up to 25 years, finding 25-year death or heart attack rates of 93.3% in the stent group versus 91% in the medical therapy group, a difference that was not statistically significant. Researchers acknowledged that heart attacks identified through routinely collected health records may be undercounted or misclassified.
The players
COURAGE Trial
The Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation trial is a landmark study that compared stenting plus medical therapy with medical therapy alone in stable coronary artery disease.
American Heart Association
The American Heart Association is a leading nonprofit organization that funds cardiovascular research and hosts its annual Scientific Sessions conference.
University of Colorado Anschutz
The University of Colorado Anschutz Medical Campus is an academic health center in Aurora, Colorado, home to the CU Anschutz School of Medicine, where the lead researchers are based.
The details
During angioplasty, doctors inflate a small balloon inside a narrowed artery to improve blood flow, and often place a tiny metal tube called a stent to help keep the artery open. The new analysis linked health records of participants, including veterans, from the original COURAGE trial, which enrolled people with stable coronary artery disease.
Timeline
Findings were presented at the 2026 American Heart Association Scientific Sessions.
The study was published in JAMA on November 7, 2026.
Health Landscape
The extended follow-up extends the original 2007 COURAGE trial, which first found that stenting added no significant benefit over optimal medical therapy for stable coronary artery disease, into a much longer timeframe. The results continue to inform debate in U.S. cardiology about how often stable patients should receive elective stent procedures compared with intensive medication management.
For people with stable coronary artery disease, the findings suggest that a stent added to medication may not reduce the chance of later death or heart attack compared with medication alone. Patients considering a procedure should discuss the long-term evidence with their cardiologist before deciding.
The takeaway
Long-term evidence from this study suggests that for stable coronary artery disease, medication remains a central option that can perform comparably to adding a stent. Patients should weigh these results with their doctor when making treatment decisions.
Further reading
Explore more on Heart Disease and how treatment approaches are evaluated over time.
Source note: This article includes information reported by SciTechDaily.
Live Poll
Would you want a stent if your doctor said your heart artery was narrowed?






